Updated:
Regenerative Medicine Minnesota
Accelerating regenerative medicine research, translation & commercialization to restore health for Minnesotans & beyond | Regenerative Medicine...
Overview
Accelerating regenerative medicine research, translation & commercialization to restore health for Minnesotans & beyond | Regenerative Medicine Minnesota (RMM) accelerates the development of breakthrough regenerative therapies for Minnesotans and beyond. We fund Minnesota-based academic institutions and small businesses advancing innovative scientific and medical research that moves regenerative solutions toward patients. By investing in strengths, addressing gaps, and supporting high-impact projects, RMM helps position Minnesota as a leader in the regenerative medicine field.
General information
Location
Region
North America
Country
United States
City
Minnesota City
Corporate office
Minnesota City, MN, United States
Sector focus
Frequently asked questions
How does the grant-review process work?
Applications are evaluated by a 16-member advisory council whose members are appointed by the governor and legislative leadership. The council uses an NIH-style peer-review framework, scoring proposals on scientific merit, feasibility and alignment with the program's translational-research mandate. Final award recommendations are published in public meeting minutes.
What types of funding does the program provide?
The program operates four distinct tracks: research grants for academic laboratories, clinical-trial support, biobusiness loans and equity investments for early-stage companies, and educational initiatives. The biobusiness track is the closest analogue to venture capital, providing convertible loans or direct equity to Minnesota-based startups at the pre-seed stage.
Which institutions have received funding?
The University of Minnesota and Mayo Clinic are the largest recipients by volume. Additional grantees include early-stage ventures spun out of the Twin Cities ecosystem, though individual company names shift with each annual grant cycle and are publicly listed in the advisory council's award announcements.
Is there any relationship between Regenerative Medicine Minnesota and private investment funds?
No formal relationship exists. The program is a standalone state initiative. However, the biobusiness track effectively acts as a pre-seed bridge that de-risks companies for later-stage private venture investors, making it an upstream pipeline player in the Minnesota life-science ecosystem.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: